InSphero at the AACR Annual Meeting 2025
Join us at the AACR 2025 in Chicago. This key event brings together professionals from the oncology research community to exchange insights, research, and innovations. We look forward to connecting with fellow attendees and engaging in valuable discussions.
Meet our Team at the AACR 2025
Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.
Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.
Laure-Anne Ligeon, PhD
Team Lead Oncology & Immunology
Laure-Anne Ligeon, PhD
Team Lead Oncology & Immunology
Laure-Anne Ligeon is the Team Lead of Oncology and Immunology Group at InSphero. She focuses on developing strategies and assays by bringing together human immunology and cell biology to model the complexity of tumor microenvironment for drug testing. Laure-Anne holds a PhD in molecular cell biology from University of Lille – Pasteur institute. Prior to joining InSphero she was a Senior Scientist at the Institute of Experimental Immunology, University of Zürich.
Sue Grepper, PhD
Director of Business Development
Sue Grepper, PhD
Director of Business Development
Sue is an experienced scientist with over 20 years of in vitro research experience. Sue holds a PhD in Pharmacology/Toxicology from the University of Arizona. She has dedicated the majority of her career to helping scientists achieve their research goals with human cell-based models.
Arnab China, PhD
Business Development Manager
Arnab China, PhD
Business Development Manager
Arnab China is a Business Development Manager at InSphero, advancing the adoption of cutting-edge 3D in vitro models for drug discovery. Previously, he played a key role in startups, driving engineered cell therapies from development to clinical trials. Arnab holds a Master’s and Ph.D. in Molecular Cell Biology from the Indian Institute of Science, Bangalore, and completed postdoctoral training in Cancer Cell Biology at the Cleveland Clinic. A founding member of STEMPeers, he advocates for biotech innovation, career development, and community building in Philadelphia.
Our Booth at the AACR 2025
Visit our booth #1007 and discover valuable insights into mechanisms of action and the effect of multiple cell types in Oncology and Immunology by using our physiologically relevant and scalable 3D Human tumor models.
Posters at the AACR 2025
Unlocking the potential of 3D patient-derived tumor microtissues as reliable and scalable in vitro pre-clinical models
Date: Monday, 28 April, 2025 | 9:00 - 12:00 PM
Poster board number: 8
Laure-Anne Ligeon, PhD
Team Lead Oncology & Immunology
Laure-Anne Ligeon, PhD
Team Lead Oncology & Immunology
Laure-Anne Ligeon is the Team Lead of Oncology and Immunology Group at InSphero. She focuses on developing strategies and assays by bringing together human immunology and cell biology to model the complexity of tumor microenvironment for drug testing. Laure-Anne holds a PhD in molecular cell biology from University of Lille – Pasteur institute. Prior to joining InSphero she was a Senior Scientist at the Institute of Experimental Immunology, University of Zürich.
Cryopreserved 3D Human Tumor Spheroid Platform in 96-well Format for Robust & Scalable Discovery and Screening
Date: Monday, 28 April, 2025 | 9:00 - 12:00 PM
Poster board number: 4
Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.
Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.
Advancing antibody therapeutics: A 3D in vitro model for penetration assessment of immunoglobulins in human tumor spheroids
Date: Monday, 28 April, 2025 | 2:00 - 5:00 PM
Poster board number: 3
Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.
Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.
Meet our partner at AACR 2025
